Mesoblast Board Changes
Stocks in this Quantisnow insightHealth Care
Historical context for MESO
Across the 29 sessions after earlier MESO headlines, the stock closed higher 17 times and lower 12 times, with a median move of 3.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | MESO | SPY |
|---|---|---|---|
| Oct 29, 2026 | Activity Report for Quarter Ended September 30, 2026 (Appendix 4C) | +17.0% | -0.4% |
| Sep 24, 2026 | Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product | +1.2% | -0.1% |
| Aug 27, 2026 | Mesoblast Reports Substantial Revenue Growth to US$120M | +8.0% | +0.7% |
| Aug 24, 2026 | Mesoblast Financial Results and Corporate Update Webcast | -2.1% | -0.3% |
| Aug 17, 2026 | Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain | +9.1% | -0.5% |
| Jul 30, 2026 | Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch | +3.0% | +1.7% |
Quantisnow market dataNASDAQ
MESO
Mesoblast Limited
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2015
Get push alerts for MESO
Full MESO profile on Quantisnow Follow MESO and get a push notification the moment its next story breaks.